# Xunmeng Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xunmeng-biotechnology

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Latest round: Angel (Feb 13, 2026)
- Investors on record: 1

## About

Founded in 2025 and based in Shenzhen, China, Xunmeng (Shenzhen) Biotechnology Co., Ltd., dba Xunmeng Biotechnology, is an innovative biotechnology company focused on engineered cell therapy, targeting major unmet clinical needs through the development of scalable and industrializable cell-based therapeutic platforms. In February 2026, Xunmeng Biotechnology raised Angel funding from new investor Vinno Capital.
The company is developing an engineered cell therapy platform with research programs spanning cardiovascular diseases, inflammatory disorders, and chronic kidney disease.
Xunmeng Biotechnology’s revenue is generated to be primarily generated from research-driven funding sources, including equity financing, government or institutional research grants, and potential early-stage research collaborations or licensing arrangements related to its engineered cell therapy platform.

## Funding rounds

- Angel, Feb 13, 2026 — Vinno Capital

## Investors

- Vinno Capital (https://capitalatlas.ai/funds/vinno-capital) — Angel